DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 102
2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
3. Claims 1-3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Wang (CN-114702798-A, machine translation used for rejection below).
As to claim 1, Wang discloses a phosphazene derivative having a structure of Formula (I) (page 2 lines 38-45, Reactant A):
PNG
media_image1.png
177
191
media_image1.png
Greyscale
wherein n is an integer of 3 to 6 (page 2 lines 38-45, Reactant A), R1 and R2 are independently selected from a group represented by Formula (I-1) or Formula (I-2) (page 2 lines 38-45, Reactant A),
PNG
media_image2.png
241
816
media_image2.png
Greyscale
wherein A is -R3-O-R4, -R3-CH3-m(OR4)m, - CH3-m(OR4)m, or -R5-(O-R6)x-OR7, wherein R3 is unsubstituted C1-C8 alkylene or C1-C8 Alkylene substituted with C1-C8 alkyl, R4 is C1-C8 alkyl, R5 is C1-C3 alkyl, x is 1 or 2, m is 2 or 3, p is a number of the A bonded to a carbon in a benzene ring to which the A is attached, and p is an integer of 0 to 3 (page 2 lines 38-45, Reactant A);
B is C1-C8 alkoxy or C1-C8 alkyl, and q is an integer of 0 to 3 (page 2 lines 38-45, Reactant A); and
0 < p + q ≤ 5 (page 2 lines 38-45, Reactant A).
As to claim 2, Wang discloses the phosphazene derivative of claim 1, and Wang further discloses wherein R1 and R2 are groups represented by Formula (I-1) (page 2 lines 38-45, Reactant A), A is -R3-O-R4, R3 is C1-C8 alkylene, R4 is C1-C8 alkyl, and p is 0 or 1 (page 2 lines 38-45, Reactant A), B is C1-C8 alkoxy, and q is 0 or 1; and 0 < p + q ≤ 2 (page 2 lines 38-45, Reactant A).
As to claim 3, Wang discloses the phosphazene derivate of claim 2, and Wang further discloses wherein the phosphazene derivative is one selected from group consisting of compounds (I-1) to (I-4) below (page 2 lines 38-45, Reactant A):
PNG
media_image3.png
838
425
media_image3.png
Greyscale
PNG
media_image4.png
451
545
media_image4.png
Greyscale
Allowable Subject Matter
4. Claims 4-13 are allowed.
5. The following is an examiner’s statement of reasons for allowance: The prior art discloses a phosphazene derivative, as discussed above, but does not disclose or suggest wherein the phosphazene derivative is used as an additive with a non-aqueous solvent in an electrolyte.
Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.”
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JACOB JEROME SCHULER whose telephone number is (571)272-8487. The examiner can normally be reached Mon-Fri. 7:30am-5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Barbara Gilliam can be reached at 5712721330. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/J.J.S./Examiner, Art Unit 1727
/Maria Laios/Primary Examiner, Art Unit 1727
Prosecution Insights